Dyne Therapeutics Demonstrating FORCE™ Platform Delivery to CNS - 2023 Meet the DM Drug Developers

Presented June 14, 2023.
Each month biotechnology, pharmaceutical and academic partners, large and small, working on treatments and a cure for myotonic dystrophy will sit down with our community to share their progress and answer your questions.
Learn more about Dyne Therapeutics at www.dyne-tx.com/
Dr. Ashish Dugar, Chief Medical Affairs Officer at Dyne Therapeutics, presents released preclinical data demonstrating that Dyne’s FORCE™ platform achieved delivery to the brain in non-human primates and robust pharmacological effects in a model of myotonic dystrophy type 1 (DM1). Q&A hosted by Molly White, Global Head of Patient Advocacy.
Find all our upcoming Meet the DM Drug Developers dates at www.myotonic.org/meet-dm-drug...

[@HiddenPreservatives]

Praying this comes out soon my wife is really sick from DM1 Myotonic Dystrophy

[@DiyaraMahamatbek]

first to approve tideglusib and aoc 1001 close to approval